Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Juengel, Eva ^a   Engler, Johanna ^a   Natsheh, Iyad ^a   Jones, Jon ^a   Mickuckyte, Ausra ^a   Hudak, Lukasz ^a   Jonas, Dietger ^a   Blaheta, Roman A ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BETA ACTIN; COLLAGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBRONECTIN; GEFITINIB; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN P70S6K; SUNITINIB; UNCLASSIFIED DRUG; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PURINE DERIVATIVE; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN A498; CELL STRAIN CAKI 1; CELL STRAIN KTC 26; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MONOTHERAPY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN IMMOBILIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; CELL CYCLE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

CARCINOMA, RENAL CELL; CELL ADHESION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PURINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIROLIMUS;

EID: 67649780941     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-161     Document Type: Article

References (38)

1. McDermott DF Atkins MB Application of IL-2 and other cytokines in renal cancer Expert Opin Biol Ther 2004, 4:455-68. 10.1517/14712598.4.4.455 15102596
2. Motzer RJ Hutson TE Tomczak P Michaelson MD Bukowski RM Rixe O Oudard S Negrier S Szczylik C Kim ST Chen I Bycott PW Baum CM Figlin RA Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 2007, 356:115-24. 10.1056/NEJMoa065044 17215529
3. Escudier B Eisen T Stadler WM Szczylik C Oudard S Siebels M Negrier S Chevreau C Solska E Desai AA Rolland F Demkow T Hutson TE Gore M Freeman S Schwartz B Shan M Simantov R Bukowski RM TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007, 356:125-34. 10.1056/NEJMoa060655 17215530
4. Ravaud A Hawkins R Gardner JP Maase von der H Zantl N Harper P Rolland F Audhuy B Machiels JP Pétavy F Gore M Schöffski P El-Hariry I Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: A randomized phase III clinical trial J Clin Oncol 2008, 26:2285-91. 10.1200/JCO.2007.14.5029 18467719
5. Jermann M Stahel RA Salzberg M Cerny T Joerger M Gillessen S Morant R Egli F Rhyner K Bauer JA Pless M A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma Cancer Chemother Pharmacol 2006, 57:533-9. 10.1007/s00280-005-0070-z 16052341
6. Viloria-Petit A Crombet T Jothy S Hicklin D Bohlen P Schlaeppi JM Rak J Kerbel RS Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis Cancer Res 2001, 61:5090-101. 11431346
7. Kedar D Baker CH Killion JJ Dinney CP Fidler IJ Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice Clin Cancer Res 2002, 8:3592-600. 12429651
8. Baselga J Tabernero J Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: Hold back, we are not there yet J Clin Oncol 2007, 25:4516-8. 10.1200/JCO.2007.12.8900 17876011
9. Robb VA Karbowniczek M Klein-Szanto AJ Henske EP Activation of the mTOR signaling pathway in renal clear cell carcinoma J Urol 2007, 177:346-52. 10.1016/j.juro.2006.08.076 17162089
10. Sourbier C Lindner V Lang H Agouni A Schordan E Danilin S Rothhut S Jacqmin D Helwig JJ Massfelder T The phosphoinositide 3-kinase/Akt pathway: A new target in human renal cell carcinoma therapy Cancer Res 2006, 66:5130-42. 10.1158/0008-5472.CAN-05-1469 16707436
11. LoPiccolo J Blumenthal GM Bernstein WB Dennis PA Targeting the PI3K/Akt/ mTOR pathway: Effective combinations and clinical considerations Drug Resist Updat 2008, 11:32-50. 2442829 18166498 10.1016/j.drup.2007.11.003
12. Traxler P Allegrini PR Brandt R Brueggen J Cozens R Fabbro D Grosios K Lane HA McSheehy P Mestan J Meyer T Tang C Wartmann M Wood J Caravatti G AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 2004, 64:4931-41. 10.1158/0008-5472.CAN-03-3681 15256466
13. Busby JE Kim SJ Yazici S Nakamura T Kim JS He J Maya M Wang X Do KA Fan D Fidler IJ Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells Prostate 2006, 66:1788-98. 10.1002/ pros.20519 17013882
14. Kuwai T Nakamura T Sasaki T Kitadai Y Kim JS Langley RR Fan D Wang X Do KA Kim SJ Fidler IJ Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy Clin Exp Metastasis 2008, 25:477-89. 10.1007/s10585-008-9153-7 18324358
15. Yokoi K Sasaki T Bucana CD Fan D Baker CH Kitadai Y Kuwai T Abbruzzese JL Fidler IJ Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model Cancer Res 2005, 65:10371-80. 1456803 16288027 10.1158/0008-5472.CAN-05-1698
16. Yu C Friday BB Lai JP McCollum A Atadja P Roberts LR Adjei AA Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation Clin Cancer Res 2007, 13:1140-8. 10.1158/ 1078-0432.CCR-06-1751 17317822
17. Failly M Korur S Egler V Boulay JL Lino MM Imber R Merlo A Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells Mol Cancer Ther 2007, 6:773-81. 10.1158/1535-7163.MCT-06-0566 17308073
18. Peng DF Sugihara H Hattori T Bromodeoxyuridine induces p53-dependent and -independent cell cycle arrests in human gastric carcinoma cell lines Pathobiology 2001, 69:77-85. 10.1159/000048760 11752901
19. Atkins DJ Gingert C Justenhoven C Schmahl GE Bonato MS Brauch H Störkel S Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas Virchows Arch 2005, 447:634-42. 10.1007/s00428-005-1262-y 15991006
20. Hedberg Y Ljungberg B Roos G Landberg G Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins Int J Cancer 2004, 109:189-93. 10.1002/ijc.11665 14750168
21. Hedberg Y Davoodi E Ljungberg B Roos G Landberg G Cyclin E and p27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D Int J Cancer 2002, 102:601-7. 10.1002/ ijc.10763 12448001
22. Migita T Oda Y Naito S Tsuneyoshi M Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma Cancer 2002, 94:973-9. 10.1002/cncr.10338 11920465
23. Yang FG Zhang ZW Xin DQ Shi CJ Wu JP Guo YL Guan YF Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines Acta Pharmacol Sin 2005, 26:753-61. 10.1111/j.1745-7254.2005.00753.x 15916743
24. Hara I Miyake H Hara S Arakawa S Kamidono S Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity Int J Oncol 2000, 17:1213-8. 11078807
25. Franco OE Onishi T Umeda Y Soga N Wakita T Arima K Yanagawa M Sugimura Y Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines Anticancer Res 2003, 23:1637-42. 12820434
26. Schuler W Sedrani R Cottens S Häberlin B Schulz M Schuurman HJ Zenke G Zerwes HG Schreier MH SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo Transplantation 1997, 64:36-42. 10.1097/00007890-199707150-00008 9233698
27. Jac J Giessinger S Khan M Willis J Chiang S Amato R A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) J Clin Oncol 2007, 25:5107.
28. O'Donnell A Faivre S Burris HA 3rd Rea D Papadimitrakopoulou V Shand N Lane HA Hazell K Zoellner U Kovarik JM Brock C Jones S Raymond E Judson I Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 2008, 26:1588-95. 10.1200/ JCO.2007.14.0988 18332470
29. Awada A Cardoso F Fontaine C Dirix L De Grève J Sotiriou C Steinseifer J Wouters C Tanaka C Zoellner U Tang P Piccart M The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics Eur J Cancer 2008, 44:84-91. 10.1016/j.ejca.2007.10.003 18039566
30. Jac J Giessinger S Khan M Willis J Chiang S Amato R A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC) (Abstract) Proc Am Soc Clin Oncol J Clin Oncol 2007, 25:5107.
31. Jac J Amato RJ Giessinger S Saxena S Willis JP A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy Proc Am Soc Clin Oncol J Clin Oncol 2008.
32. Motzer RJ Escudier B Oudard S Hutson TE Porta C Bracarda S Grünwald V Thompson JA Figlin RA Hollaender N Urbanowitz G Berg WJ Kay A Lebwohl D Ravaud A RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial Lancet 2008, 372:449-56. 10.1016/S0140-6736(08)61039-9 18653228
33. Goudar RK Shi Q Hjelmeland MD Keir ST McLendon RE Wikstrand CJ Reese ED Conrad CA Traxler P Lane HA Reardon DA Cavenee WK Wang XF Bigner DD Friedman HS Rich JN Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol Cancer Ther 2005, 4:101-12. 15657358
34. Azzariti A Porcelli L Gatti G Nicolin A Paradiso A Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells Biochem Pharmacol 2008, 75:1035-44. 10.1016/ j.bcp.2007.11.018 18191814
35. Masiello D Mohi MG McKnight NC Smith B Neel BG Balk SP Bubley GJ Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer Cancer Biol Ther 2007, 6:195-201. 17218776
36. Buck E Eyzaguirre A Brown E Petti F McCormack S Haley JD Iwata KK Gibson NW Griffin G Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol Cancer Ther 2006, 5:2676-84. 10.1158/ 1535-7163.MCT-06-0166 17121914
37. Huynh H Ngo VC Koong HN Poon D Choo SP Thng CH Chow P Ong HS Chung A Soo KC Sorafenib and Rapamycin Induce Growth Suppression in Mouse Models of Hepatocellular Carcinoma J Cell Mol Med 2009. 19220580
38. Le Tourneau C Faivre S Serova M Raymond E mTORC1 inhibitors: Is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008, 99:1197-203. 10.1038/sj.bjc.6604636 18797463